VistaGen CEO notes broad market potential of ketamine-like AV-101 - The Pharma Letter

Submitted by Anonymous (not verified) on Mon, 11/26/2018 - 08:00

VistaGen CEO notes broad market potential of ketamine-like AV-101  The Pharma LetterIn the USA alone, more than 10% of adults or adolescents take antidepressants, and fully two-thirds of these people do not respond to first-line treatment, norm.